Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
The Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
1 other identifier
observational
12
1 country
2
Brief Summary
This research study will help us learn more about how chronic graft-versus-host disease affects the skin, hair and nails. We are interested in knowing if hair and nail problems predict worse disease. This information may help us treat patients like you in the future.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2010
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2010
CompletedFirst Submitted
Initial submission to the registry
October 14, 2010
CompletedFirst Posted
Study publicly available on registry
October 15, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2014
CompletedMarch 31, 2015
March 1, 2015
2.6 years
October 14, 2010
March 27, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Adnexal involvement
To determine if adnexal involvement predicts worse severity and/or prognosis in chronic GVHD. This will be measured by administration of systemic therapy other than steroids.
1 year
Eligibility Criteria
The research subject population is children who have received hematopoietic stem cell transplant and developed chronic graft-versus-host disease. All children seen at the pediatric GVHD clinic at the Dana-Farber Cancer Institute will be recruited.
You may qualify if:
- Received hematopoietic stem cell transplant
- Meet the diagnostic criteria for cutaneous cGVHD
You may not qualify if:
- Previous HSCT (other then the current HSCT)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Children's Hospital Boston
Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jennifer Huang, MD
Boston Children's Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Instructor in Dermatology
Study Record Dates
First Submitted
October 14, 2010
First Posted
October 15, 2010
Study Start
September 1, 2010
Primary Completion
April 1, 2013
Study Completion
October 1, 2014
Last Updated
March 31, 2015
Record last verified: 2015-03